Tag: phase II trial

A prospective phase II trial reports that orelabrutinib combined with sintilimab achieved a 60.7 percent response rate and a median ...

A Phase II trial in Japan identified TCR signaling mutations and clonal hematopoiesis burden as biomarkers predicting dasatinib response in ...

A phase II trial of 24 Chinese patients with higher-risk chronic myelomonocytic leukemia found that the SIRPα-Fc fusion protein timdarpacept ...

A phase II trial reports 11.9-month median overall survival with CIMAvax-EGF plus nivolumab in previously treated advanced NSCLC, with the ...

A new phase II trial protocol will test whether AGuIX nanoparticles, already shown to be tolerated at 100 mg/kg in ...

The final MegaMOST analysis found trametinib did not meet its efficacy boundary in molecularly selected advanced solid tumours, though a ...

The 50-patient COMPORT phase II trial will prospectively evaluate whether pathology-based omission of low-risk anatomical compartments can individualize postoperative radiotherapy ...

A small, uncontrolled phase II trial associated eight weeks of oxaloacetate with improved cognition, fatigue and physical functioning in 16 ...

A small, single-arm phase II study found a 56.3% response rate with first-line cadonilimab plus PF chemotherapy in 16 patients ...

In a prospective, multicenter, single-arm phase II trial conducted at four centers in China, orelabrutinib plus R-CDOP was associated with ...

A single-arm phase II trial of 40 patients with locally advanced esophagogastric junction adenocarcinoma reported high pathological response rates, manageable ...

A phase II trial found that prophylactic pirfenidone significantly reduced grade 2 or higher radiation-induced lung injury in lung cancer ...

A multicenter phase II trial found that a pyrotinib-based neoadjuvant regimen achieved pathological response rates comparable to the standard trastuzumab-pertuzumab ...

A phase II trial found that preoperative chemo-immunotherapy with sintilimab achieved major pathological responses in 59.1 percent of locally advanced ...

A German phase II trial called TRITICC-2 is testing whether oral trifluridine/tipiracil combined with nanoliposomal irinotecan can improve outcomes for ...

A groundbreaking advancement in the fight against non-small-cell lung cancer (NSCLC) has emerged from a recent multicenter phase II study ...

In a groundbreaking advance that could redefine the therapeutic landscape for liver cancer, a new single-arm phase II clinical trial ...